Better Buy: Illumina vs. Guardant Health
Which stock wins in a matchup between a gene sequencing pioneer and a fast-rising liquid biopsy leader?
Illumina
ILMN
ILMN
$305.20
$2.19
0.7%
BATS BZX Real Time Price as of September 19, 2019, 4:00 p.m. EDT
View Interactive ILMN Charts
Illumina is a developer, manufacturer and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function.
News & Analysis: Illumina
The Fool has written over 400 articles on Illumina.
Merger or Not, Pacific Biosciences Needs to Deliver
The DNA sequencing pioneer promised a $1,000 human genome by early 2019. The price isn't so important, but the technology upgrades will prove critical.
My 3 Top Healthcare Stocks for Long-Term Investors
They're pioneers. They're innovators. And they should continue to be huge winners for investors with long-term perspectives.
5 Top Cancer-Fighting Stocks to Buy Now
Each of these healthcare companies takes a different approach to fighting cancer, but all have what it takes to be long-term winners in your portfolio.
Here's Why Illumina Tumbled 18.7% in July
Growth stagnated in the first half of 2019. Management says it will be temporary.
5 Things Illumina's Management Just Said That You'll Really Want to Know
Are the disappointing results for Illumina a "new normal"? Not at all, according to its top executives.
Illumina Inc (ILMN) Q2 2019 Earnings Call Transcript
ILMN earnings call for the period ending June 30, 2019.
Illumina Hits a Speed Bump in the Second Quarter
The genomic sequencing company reported slower revenue growth because of several issues, including a delay in closing a major population genomics deal.
10 Biggest Medical Device Stocks
Market caps for these medical device stocks are big. Most of them have been big winners, too.
What Happens If Pacific Biosciences Isn't Acquired By Illumina?
Abandoning the proposed deal would have a seismic effect on the future of DNA sequencing, but it's not all bad news for investors.
